within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF10_Entecavir;

model Entecavir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 1,
    Cl = 3.888888888888889e-06,
    adminDuration = 600,
    adminMass = 0.5 / 1000000,
    adminCount = 1,
    Vd = 0.076,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.021500000000000002,
    Tlag = 10.200000000000001,
    Vdp = 0.239,
    k12 = 2.6111111111111113e-06,
    k21 = 2.6111111111111113e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Entecavir</td></tr><tr><td>ATC code:</td><td>J05AF10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>76</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Entecavir is a nucleoside analogue with potent and selective activity against hepatitis B virus (HBV). It inhibits the HBV DNA polymerase, reducing viral replication. It is approved for the treatment of chronic hepatitis B infection in adults and pediatric patients over 2 years of age.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following single oral administration.</p><h4>References</h4><ol><li><p>Yoshitsugu, H, et al., &amp; Hiraoka, M (2011). Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. <i>Diagnostic microbiology and infectious disease</i> 70(1) 91–100. DOI:<a href=\"https://doi.org/10.1016/j.diagmicrobio.2010.12.009\">10.1016/j.diagmicrobio.2010.12.009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21513847/\">https://pubmed.ncbi.nlm.nih.gov/21513847</a></p></li><li><p>Zhu, M, et al., &amp; Pfister, M (2008). Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. <i>Antimicrobial agents and chemotherapy</i> 52(8) 2836–2841. DOI:<a href=\"https://doi.org/10.1128/AAC.01366-07\">10.1128/AAC.01366-07</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18391039/\">https://pubmed.ncbi.nlm.nih.gov/18391039</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AF10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Entecavir;
